The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Daily Cannabis Smoking as a Risk Factor for Progression of Fibrosis in Chronic Hepatitis C *
Abstract
Cannabinoids present in Cannabis sativa (marijuana) exert biological effects via cannabinoid receptors CB1 and CB2. We recently demonstrated that CB1 and CB2 receptors regulate progression of experimental liver fibrosis. We therefore investigated the impact of cannabis smoking on fibrosis progression rate in patients with chronic hepatitis C (CHC). Two hundred seventy consecutive untreated patients with CHC of known duration undergoing liver biopsy were studied. Demographic, epidemiological, metabolic, and virological data were recorded, and detailed histories of cannabis, alcohol, and tobacco use over the span of hepatitis C virus infection were obtained. Fibrosis stage, steatosis, and activity grades were scored according to Metavir system. Patients were categorized as noncannabis users (52.2%), occasional users (14.8%), or daily users (33.0%), and the relationship between cannabis use and fibrosis progression rate (FPR) or fibrosis stage was assessed. On multivariate analysis, six factors were independently related to a FPR greater than 0.074 (median value of the cohort): daily cannabis use (OR = 3.4 [1.5-7.4]), Metavir activity grade A2 or higher (OR = 5.4 [2.9-10.3]), age at contamination of more than 40 years (OR = 10.5 [3.0-37.1]), genotype 3 (OR = 3.4 [1.5-7.7]), excessive alcohol intake (OR = 2.2 [1.1-4.5]), and steatosis (OR = 2.0 [1.0-4.1]). Daily cannabis use was also an independent predictor of a rapid FPR (>0.15) (OR = 3.6 [1.5-7.5]). Finally, severe fibrosis (≥F3) was also predicted by daily cannabis use (OR = 2.5 [1.1-5.6]; P = .034), independently of Metavir activity grade, excessive alcohol intake, age at liver biopsy, steatosis, and tobacco smoking. In conclusion , daily cannabis smoking is significantly associated with fibrosis progression during CHC. Patients with ongoing CHC should be advised to refrain from regular cannabis use. (Hepatology 2005;.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
Adinolfi, L. E., Gambardella, M., Andreana, A., Tripodi, M.-F., Utili, R., & Ruggiero, G. (2001) · Hepatology · doi:10.1053/jhep.2001.24432 · Cited by 1,059
The natural history of drug use from adolescence to the mid-thirties in a general population sample
Chen, K., & Kandel, D. B. (1995) · American Journal of Public Health · doi:10.2105/ajph.85.1.41 · Cited by 857
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
Poynard, T., Ratziu, V., Charlotte, F., Goodman, Z., McHutchison, J., & Albrecht, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00097-0 · Cited by 749
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Fibrosis in Chronic Hepatitis C Correlates Significantly With Body Mass Index and Steatosis
Hourigan, L. F., Macdonald, G. A., Purdie, D., Whitehall, V. H., Shorthouse, C., Clouston, A., & Powell, E. E. (1999) · Hepatology · doi:10.1002/hep.510290401 · Cited by 674
The Long–Term Pathological Evolution of Chronic Hepatitis C
Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., Inoue, O., Hashimoto, E., Lefkowitch, J. H., Ludwig, J., & Okuda, K. (1996) · Hepatology · doi:10.1002/hep.510230607 · Cited by 598
Estimating future hepatitis C morbidity, mortality, and costs in the United States
(2000) · American Journal of Public Health · doi:10.2105/ajph.90.10.1562 · Cited by 567
Prevalence of Marijuana Use Disorders in the United States: 1991-1992 and 2001-2002
Compton, W. M., Grant, B. F., Colliver, J. D., Glantz, M. D., & Stinson, F. S. (2004) · JAMA · doi:10.1001/jama.291.17.2114 · Cited by 537
The cannabinoid system and immune modulation
Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., & Friedman, H. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 524
Antifibrogenic role of the cannabinoid receptor CB2 in the liver
Julien, B., Grenard, P., Teixeira-Clerc, F., Van Nhieu, J. T., Li, L., Karsak, M., Zimmer, A., Mallat, A., & Lotersztajn, S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.050 · Cited by 470
Self-citationBátkai, S., Járai, Z., Wagner, J. A., Goparaju, S. K., Varga, K., Liu, J., Wang, L., Mirshahi, F., Khanolkar, A. D., Makriyannis, A., et al. (2001) · Nature Medicine · doi:10.1038/89953 · Cited by 378
Pessione, F., Degos, F., Marcellin, P., Duchatelle, V., Njapoum, C., Martinot-Peignoux, M., Degott, C., Valla, D., Erlinger, S., & Rueff, B. (1998) · Hepatology · doi:10.1002/hep.510270635 · Cited by 340
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Self-citationRoudot-Thoraval, F., Bastie, A., Pawlotsky, J., & Dhumeaux, D. (1997) · Hepatology · doi:10.1002/hep.510260233 · Cited by 297
Self-citationSteatosis affects chronic hepatitis C progression in a genotype specific way
Rubbia-Brandt, L., Fabris, P., Paganin, S., Leandro, G., Male, P.-J., Giostra, E., Carlotto, A., Bozzola, L., Smedile, A., & Negro, F. (2004) · Gut · doi:10.1136/gut.2003.018770 · Cited by 297
Role of alcohol in the progression of liver disease caused by hepatitis C virus infection
Ostapowicz, G., Watson, K. J., Locarnini, S. A., & Desmond, P. V. (1998) · Hepatology · doi:10.1002/hep.510270637 · Cited by 286
Westin, J., Nordlinder, H., Lagging, M., Norkrans, G., & Wejstål, R. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00299-4 · Cited by 280
Fibrosis and disease progression in hepatitis C
Marcellin, P., Asselah, T., & Boyer, N. (2002) · Hepatology · doi:10.1002/hep.1840360707 · Cited by 267
Epidemiology of substance use in adolescence: prevalence, trends and policy implications
Bauman, A., & Phongsavan, P. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00016-2 · Cited by 263
Ros, J., Clària, J., To–Figueras, J., Planagumà, A., Cejudo–Martín, P., Fernández–Varo, G., Martín–Ruiz, R., Arroyo, V., Rivera, F., Rodés, J., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.30305 · Cited by 240
Contribution of obesity to hepatitis C-related fibrosis progression
Ortiz, V (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04352-6 · Cited by 233
Cigarette Smoking and Hepatic Lesions in Patients With Chronic Hepatitis C
Pessione, F., Ramond, M.-J., Njapoum, C., Duchatelle, V., Degott, C., Erlinger, S., Rueff, B., Valla, D.-C., & Degos, F. (2001) · Hepatology · doi:10.1053/jhep.2001.25385 · Cited by 207
Risks of a range of alcohol intake on hepatitis C-related fibrosis
Monto, A., Patel, K., Bostrom, A., Pianko, S., Pockros, P., McHutchison, J. G., & Wright, T. L. (2004) · Hepatology · doi:10.1002/hep.20127 · Cited by 173
Drug use and drinking among students in 36 countries
Smart, R. G., & Ogborne, A. C. (2000) · Addictive Behaviors · doi:10.1016/s0306-4603(99)00013-1 · Cited by 160
Predictors of cessation of marijuana use: an event history analysis
Chen, K. M., & Kandel, D. B. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00021-0 · Cited by 155
Fibrogenic impact of high serum glucose in chro nic hepatitis C
Ratziu, V., Munteanu, M., Charlotte, F., Bonyhay, L., & Poynard, T. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00456-2 · Cited by 153
Wright, M., Goldin, R. D., Fabre, A., Lloyd, J., Thomas, H. C., TREPO, C. G., Pradat, P., & Thursz, M. R. (2003) · Gut · doi:10.1136/gut.52.4.574 · Cited by 132
Hézode, C., Lonjon, I., Roudot‐Thoraval, F., Pawlotsky, J., Zafrani, É. S., & Dhumeaux, D. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01546.x · Cited by 128
Self-citationAsselah, T., Boyer, N., Guimont, M.-C., Cazals-Hatem, D. L., Tubach, F., Nahon, K., Daïkha, H., Vidaud, D., Martinot-Peignoux, M., Vidaud, M., et al. (2003) · Gut · doi:10.1136/gut.52.11.1638 · Cited by 127
Impact of smoking on histological liver lesions in chronic hepatitis C
Hézode, C., Lonjon, I., Roudot‐Thoraval, F., Mavier, J.-P., Pawlotsky, J., Zafrani, E. S., & Dhumeaux, D. (2002) · Gut · doi:10.1136/gut.52.1.126 · Cited by 122
Self-citationHepatitis activity index is a key factor in determining the natural history of chronic hepatitis C
Fontaine, H., Nalpas, B., Poulet, B., Carnot, F., Zylberberg, H., Bréchot, C., & Pol, S. (2001) · Human Pathology · doi:10.1053/hupa.2001.28228 · Cited by 92
One year follow-up of cannabis dependence among long-term users in Sydney, Australia
Swift, W., Hall, W., & Copeland, J. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00131-3 · Cited by 74
Adlaf, E. M., Paglia, A., Ivis, F. J., & Ialomiteanu, A. (2000) · PubMed Central · Cited by 28
20 Reduced liver fibrosis in CB1 receptor knockout mice
Grenard, P., Julien, B., Nhieu, J. T. V., Li, L., Ledent, C. A., Mallat, A., & Lotersztajn, S. (2004) · Journal of Hepatology · doi:10.1016/s0168-8278(04)90020-7 · Cited by 8
Self-citationAlberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
Cited by
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60121-5 · Cited by 1,740
The global burden of hepatitis C
Lavanchy, D. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01934.x · Cited by 1,368
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Metadata
- Authors
- Hézode, C., Roudot-Thoraval, F., Nguyen, S., Grenard, P., Julien, B., Zafrani, E.-S., Pawlostky, J.-M., Dhumeaux, D., Lotersztajn, S., & Mallat, A.
- Venue
- Hepatology
- Published
- 2005-07
- Volume
- 42
- Issue
- 1
- Pages
- 63-71
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2001427377
- Cited by
- 293
- References
- 39
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.